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Influenza A virus infections impose a recurrent and global disease burden. Current antivirals against influenza are
not always effective.We assessed the protective potential ofmonovalent and bivalent Nanobodies (Ablynx) against
challenge with this virus. These Nanobodies were derived from llamas and target H5N1 hemagglutinin. Intranasal
administration of Nanobodies effectively controlled homologous influenza A virus replication. Administration of
Nanobodies before challenge strongly reduced H5N1 virus replication in the lungs and protected mice from
morbidity and mortality after a lethal challenge with H5N1 virus. The bivalent Nanobody was at least 60-fold
more effective than the monovalent Nanobody in controlling virus replication. In addition, Nanobody therapy
after challenge strongly reduced viral replication and significantly delayed time to death. Epitope mapping
revealed that the VHH Nanobody binds to antigenic site B in H5 hemagglutinin. Because Nanobodies are small,
stable, and simple to produce, they are a promising, novel therapeutic agent against influenza.
Highly pathogenic avian influenza (HPAI) H5N1
viruses pose a pandemic threat. Transmission of these
viruses from birds to humans occurs rarely, but when it
does, it often results in severe pulmonary and systemic
disease with a mortality rate of 60%. Despite the avail-
ability of medicines designed to interfere with influenza
viral functions [1], clinicians have very limited evidence-
based intervention options to successfully treat victims
of these zoonotic infections with HPAI H5N1. Currently
licensed anti-influenza drugs are small molecules that
target the ion channel activity of matrix protein 2
(amantadine and rimantadine) or the viral neuramini-
dase (oseltamivir and zanamivir). These drugs are
beneficial in cases of uncomplicated influenza caused by
susceptible influenza virus strains [2]. However,
infection with HPAI H5N1 virus is often characterized
by a more serious clinical outcome than uncomplicated
influenza. This difference in severity can be attributed to
the higher replication rate of HPAI H5N1 viruses, their
broader cellular tropism and, sometimes, systemic
spread [3–5]. Effective treatment and control of rapidly
replicating HPAI H5N1 viruses (eg, with oseltamivir)
may therefore require higher doses to obtain and
maintain sufficient systemic drug concentrations [6].
Inadequate dosing, combined with prolonged virus
replication, increases the odds of developing resistant
virus strains [7, 8].
Severe infection with HPAI H5N1 is associated with
an aberrant host immune response, producing high
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levels of circulating proinflammatory cytokines and chemokines
[9]. Such potentially life-threatening cytokine deregulation is
presumably caused by the unusual cellular and tissue tropism of
HPAI H5N1 viruses, their rapid replication and the intrinsically
high cytopathic outcome [10]. A combination of antiviral drugs
and immunomodulators could be used to manage infection with
HPAI H5N1, but such an intervention is not without risks [11–
13]. Therefore, there is a need for novel anti-influenza drugs to
treat patients with severe disease resulting from infection with
highly pathogenic influenza viruses, or severe influenza in general.
Human or animal-derived immune serum with high titers of
immunoglobulins against a particular virus has been used suc-
cessfully to prevent and treat viral infections. For example,
during the Spanish flu outbreak, passive immunotherapy with
human convalescent blood products was used to treat patients
with influenza pneumonia, with some success [14, 15]. A report
from 2007 describes the transfer of convalescent plasma from
a survivor of H5N1 influenza to treat a hospitalized 31-year-old
patient with the same infection who had not responded to
oseltamivir treatment. The patient recovered completely [16].
Compared with human immunoglobulin products, recombi-
nant monoclonal antibodies or antibody-derived fragments are
safer, better characterized, and more reliable therapeutics [17,
18]. The antigen-binding site of conventional antibodies resides
in the paired variable domains of the heavy and light immu-
noglobulin chains. Antigen specificity is usually retained in
recombinant single-chain variable fragment molecules, which
typically comprise the variable heavy and variable light chain
fragments from natural antibodies, linked by a flexible peptide
[19], but antibodies with still smaller antigen-binding domains
also exist naturally. Camelids and sharks produce immuno-
globulins composed only of heavy chains, and the antigen-
binding site of these antibodies resides in a single protein
domain, designated VHH (or Nanobody [Ablynx]) in camelids
[20, 21]. VHHs can be selected by phage or other display
technologies, they are easily produced in robust recombinant
expression systems, and they have high solubility and thermal
stability. In addition, they can form long, fingerlike loops that
can penetrate into the cavities of immunogens, and their small
size permits good tissue penetration in vivo [22]. These char-
acteristics have spurred the development of VHH-based pro-
teins as novel therapeutic and diagnostic tools directed against
multiple targets, including cytokines, enzymes, bacterial toxins,
tumor antigens, microbial antigens, and parasites [23–28].
Here,wedescribe anovel treatment strategy forH5N1 influenza
virus infection, based on recombinant neutralizing Nanobodies
directed against hemagglutinin (HA). We show that intranasal
administration of a Nanobody specific for H5N1-HA potently
suppresses replication of a recombinant H5N1 virus in vivo. We
also demonstrate that a bivalent H5N1-HA–specific Nanobody is
at least 60-fold more effective at suppressing virus replication
than its monovalent counterpart, as deduced from an in vivo
dose-response comparison, and that it protects against a lethal
H5N1 virus challenge. Analysis of selected escape mutant viruses
allowed us to map the epitope of the protective Nanobody at the
site corresponding to the antigenic site B in the HA molecule.
MATERIALS AND METHODS
Selection, Expression and Purification of H5 HA–Specific VHH
Nanobodies
The recombinant H5N1-HA–specific VHHs (H5-VHH) Nano-
bodies used in this study have been described elsewhere (Anna
Hultberg, Nigel J. Temperton, Vale´rie Rosseels, Mireille Koend-
ers, Maria Gonzalez-Pajuelo, Bert Schepens, Lorena Itatı´ Iba-
n˜ez, Peter Vanlandschoot, Joris Schillemans, Michael Saunders,
Robin A. Weiss, Xavier Saelens, Jose´ A. Melero, C. Theo Ver-
rips, Steven Van Gucht, and Hans J. De Haard, unpublished
report). In brief, 2 llamas were immunized with recombinant
clade 1 A/Vietnam/1203/2004 H5N1-HA (Protein Sciences) in
Specol adjuvant. After 6 immunizations, total RNA was ex-
tracted from peripheral blood lymphocytes, converted into
complementary DNA (cDNA), and cloned in a phagemid
vector to generate a VHH phage display library. Phages carry-
ing H5N1-HA–specific Nanobodies were selected by panning
on immobilized H5N1-HA. The VHH-coding sequences from
enriched phages were cloned into an Escherichia coli expression
vector and purified from the bacterial periplasmic fraction by
immobilized metal-affinity chromatography. Recombinant
H5-VHHm Nanobody was used in this study. H5-VHHm
Nanobody was also engineered into bivalent H5-VHHb, by
linking 2 H5-VHHm domains with a glycine-serine linker. For
a negative control VHH, we used recombinant monovalent
respiratory syncytial virus (RSV) RSV-VHHm or bivalent RSV-
VHHb (Hultberg et al, unpublished report). The endotoxin
content of the purified, recombinant VHH antibodies was ,1
EU/lg of protein, as determined with the limulus amebocyte
lysate test.
H5N1 Influenza Virus
H5N1 influenza A virus NIBRG-14 was obtained from the UK
National Institute for Biological Standards and Control, a center
of the Health Protection Agency. NIBRG-14 is a 2:6 reverse
genetics–derived reassortant of A/Vietnam/1194/2004 (H5N1)
and A/PR/8/34 (H1N1) viruses. The HA- and neuraminidase-
coding segments of NIBRG-14 are from A/Vietnam/1194/2004,
but the HA segment lacks the polybasic cleavage site. NIBRG-14
virus was passaged 7 times in specific-pathogen–free BALB/c
mice to obtain a mouse-adapted derivative (NIBRG-14ma) and
propagated in Madin-Darby canine kidney (MDCK) cells. The
HA-coding region was sequenced and found to be identical in
NIBRG-14 and NIBRG-14ma viruses. The median tissue culture
infectious dose (TCID50) and median lethal dose (LD50) of
NIBRG-14ma virus were determined using the method of
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Reed and Muench [29]; 1 LD50 of mouse-adapted NIBRG-14
corresponds to 50 TCID50. All experiments with NIBRG-14
and NIBRG-14ma viruses were performed in biosafety level 2
rooms with negative pressure relative to adjoining rooms.
Binding of Nanobodies to H5 HA
The affinity and avidity of myc-tagged H5-VHHm and VHHb
were compared by performing an enzyme-linked immunosor-
bent assay on NIBRG-14ma–infected MDCK cells and on
immobilized virions. MDCK cells were infected with 100
TCID50 of NIBRG-14ma, and 8 h later cells were fixed with 4%
paraformaldehyde. Binding of Nanobodies was revealed with an
anti-myc monoclonal (Invitrogen) followed by horseradish
peroxidase–labeled anti-mouse antibody (GE Healthcare) and
horseradish peroxidase substrate (BD optEIA).
Prophylactic and Therapeutic Efficacy Studies in Mice
All animal procedures were approved by the Institutional Ethics
Committee on Experimental Animals. Specific-pathogen–free
female BALB/c mice, 7–9 weeks old, were purchased from
Charles River (Germany) and used for all experiments. Mice
were housed in cages individually ventilated with high-efficiency
particulate air filters in temperature-controlled, air-conditioned
facilities with food and water ad libitum. Mice were anesthetized
by intraperitoneal injection of xylazine (10 lg/g) and ketamine
(100 lg/g) before intranasal administration of Nanobodies or
challenge virus (50 lL, divided equally between the nostrils).
Nanobodies were diluted in endotoxin-free phosphate-buffered
saline (PBS) with 1% (wt/vol) bovine serum albumin and
administered as a single dose, ranging from 100 to 0.5 lg per
mouse (5–0.25 mg/kg). Depending on the experiment, Nano-
bodies were administered up to 72 h before or after challenge, as
specified in the figure legends.
To determine the effect of intranasal Nanobody delivery
on lung virus titer production, mice were challenged with
1 LD50 of NIBRG-14ma virus and killed 4 days after challenge.
Lung homogenates were prepared in PBS, cleared by centrifu-
gation at 4C, and used for virus titration. Monolayers of
MDCK cells were infected with 50 lL of serial 1:10 dilutions
of the lung homogenates, in a 96-well plate in serum-free
Dulbecco’s modified Eagle medium (Invitrogen) supplemented
with penicillin and streptomycin. After 1 h, the inoculum
was replaced by medium containing 2 lg/ml of L-(tosylamido-
2-phenyl) ethyl chloromethyl ketone–treated trypsin (Sigma).
End-point virus titers were determined by hemagglutination of
chicken red blood cells and expressed as TCID50 per milliliter.
Influenza RNA levels were determined with quantitative
polymerase chain reaction (PCR). RNA was isolated from 150
lL of cleared lung homogenate using the Nucleospin RNA virus
kit (Machery-Nagel). The relative amount of NIBRG-14ma
genomic RNA was determined by preparing viral cDNA and
performing quantitative PCR with M-genomic segment
primers 5’tcgaaaggaacagcagagtg3’ and 5’ccagctctatgctgacaaaatg3’
and probe 5’ggatgctg3’ (probe no. 89; Universal ProbeLibrary,
Roche) and the LightCycler 480 Real-Time PCR System
(Roche).
To determine the degree of protection against mortality,
mice were challenged with 4 LD50 of NIBRG-14ma virus and
subsequently monitored for 14 days. A 25% loss in body weight
was the end point at which moribund mice were euthanized.
Selection and Characterization of H5N1-HA–Specific VHH
Escape Mutant Viruses
In vitro NIBRG-14ma escape viruses were isolated
independently by selection with H5-VHHm and H5-VHHb
Nanobodies. Virus was serially diluted and used to infect MDCK
cells in the presence of H5-VHHm (5 lmol/L, corresponding
to 500-fold the median inhibitory concentration in micro-
neutralization) or H5-VHHb (0.05 lmol/L, corresponding to
5000-fold the median inhibitory concentration in micro-
neutralization). Escape viruses were selected using standard
techniques. After 10 passages in the presence of Nanobodies,
escape viruses were plaque purified by growth on MDCK cells
overlaid with 0.6% low-melting agarose in the presence of
Nanobodies. Six escape virus isolates obtained by selection with
H5-VHHm and 6 by selection with H5-VHHb were amplified
on MDCK cells, still in the presence of the respective Nano-
bodies. Total RNA was extracted from the supernatant and
used to clone the cDNA corresponding to the HA and M viral
RNA (vRNA) segments, as described elsewhere [30]. In parallel,
HA- and M-vRNA segments from the parental NIBRG-14ma
were also cloned. Deduced amino acid substitutions in the HA
sequence of escape viruses were modeled with PyMOLMolecular
Graphics System (W. L. DeLano, 2002; DeLano Scientific) using
the H5 HA structure with PDB code 2IBX [31]. Hemagglutina-
tion inhibition, receptor-binding experiments (using chicken and
human erythrocytes, respectively), and microneutralization were
performed as described elsewhere [32].
Statistical Analysis
SigmaPlot software (version 11) was used for statistical analysis.
Differences between groups were tested using the Kruskal-Wallis
1-way analysis of variance on ranks. When this test demon-
strated a significant difference between groups (P , .05),
2 correcting methods for multiple comparisons were used
(Dunn’s and Tukey’s tests); t tests were used to compare
2 groups. Kaplan-Meier survival curves were plotted and
evaluated.
RESULTS
Prophylactic Therapy with H5N1-HA–Specific Nanobodies
Nanobodies with clade 1 and clade 2 H5N1 virus neutralization
activity have been described elsewhere (Hultberg et al,
unpublished report). Bivalent H5-VHHb had a higher affinity
and avidity for viral HA than its monovalent counterpart
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H5-VHHm, in particular when binding to immobilized virions
(Figure 1). We extended these finding using a mouse model
for H5N1 challenge. Mice were administered PBS or 100 lg
(5 mg/kg) of H5-VHHb or negative control RSV-VHHb
intranasally at 4, 24 or 48 h before infection with 1 LD50 of
NIBRG-14ma virus. Weight loss was monitored daily, and on
day 4 mice were killed to determine virus replication in the
lungs. All mice that received H5-VHHb retained their original
body weight, whereas those receiving PBS or RSV-VHHb
gradually lost weight (Figure 2A). Importantly, intranasal
administration of H5-VHHb at 4 or 24 h before challenge did
not result in detectable lung virus titers. When animals were
treated with H5-VHHb 48 h before challenge, virus titers were
50-fold lower than in PBS and RSV-VHHb treated mice, and 3
of 7 animals had no detectable virus titers (Figure 2B).
In vitro, H5-VHHb had a 1000-fold higher virus neutralizing
activity than H5-VHHm. We therefore compared the protective
efficacy of monovalent H5-VHHm and bivalent H5-VHHb by
administering different doses of the bivalent Nanobody, ranging
from 60 to 0.5 lg per mouse (3 to 0.025 mg/kg) and equimolar
amounts of the monovalent Nanobody (30 to 0.25 lg per
mouse, corresponding to 1.5 to 0.012 mg/kg), 4 h before chal-
lenge. For up to 4 days after challenge, none of the mice treated
with mono- or bivalent H5-specific VHH Nanobodies lost
weight, but control VHH-treated mice lost up to 15% of their
initial body weight (Figure 3A). Mice treated with PBS or
with control VHH had lung virus titers ranging from 53 107 to
1 3 109 TCID50/mL, whereas the virus titers in lung extracts
from animals that received the highest dose of mono- or
bivalent H5-VHH were below the detection limit (Figure 3B).
Figure 1. Binding of mono- and bivalent Nanobodies to H5N1 virus
hemagglutinin (HA). A, Madin-Darby canine kidney cells were infected
with 100-fold the median tissue culture infectious dose of NIBRG-14ma;
8 h later, binding of monovalent H5-VHHm and bivalent H5-VHHb, applied
as 3-fold dilutions, was revealed by enzyme-linked immunosorbent assay
(ELISA). Nanobodies specific for respiratory syncytial virus protein F (RSV-
VHH) were used as negative controls. B, ELISA plates were coated with
NIBRG-14ma virus (8 or 32 HA units, as indicated) to compare binding of
mono- and bivalent Nanobodies (applied as 3-fold dilutions) by ELISA.
Error bars represent standard deviations of the mean, calculated from 2
independent experiments performed in triplicate.
Figure 2. H5-VHHb inhibits replication of H5N1 virus in mice. A,
Groups of 6–8-week-old BALB/c mice were given 100 lg of bivalent H5-
VHHb, irrelevant control respiratory syncytial virus (RSV) VHHb or
phosphate-buffered saline (PBS) intranasally at different time points
before challenge with the median lethal dose of NIBRG-14ma virus.
Subsequently, body weight was measured daily and is represented as the
percentage of initial body weight. When mice were treated 4 or 48 h
before infection, differences in body weight between the H5-VHHb and
PBS groups were statistically significant (P , .01; analysis of variance).
When mice were treated 24 h before infection, the differences between
mice treated with H5-VHHb and both the PBS and RSV-VHHb groups were
statistically significant (P , .05; t test). B, All mice were treated as
described for A and killed on day 4 after challenge, and lung virus titers
were determined. Graphs represent mean virus titers (median tissue
culture infectious dose [TCID50]/mL lung homogenate) for all mice in each
group; error bars, standard deviations of the mean; #, below detection
limit. *P , .05; **P , .005.
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Remarkably, prophylactic treatment with as little as 0.5 lg
of H5-VHHb resulted in lung virus titers that were below the
detection limit. It should be noted that we detected a low titer of
virus in 1 of 4 mice treated with 12 lg of H5-VHHb Nanobody.
Although the monovalent H5-VHHmwas a less potent inhibitor
of virus replication, treatment of mice with 6 or 1.2 lg of this
molecule still resulted in significantly lower virus titers than in
controls (Figure 3B).
Finally, we determined the protective efficacy of H5-VHHb
over a longer period and with a higher challenge dose. As shown
in Figure 4, mice that received 60 lg of H5-VHHb Nanobody 24
h before challenge with 4 LD50 of NIBRG-14ma were completely
protected and displayed no weight loss, whereas all control mice
had died or were moribund and had to be euthanized by day 8
after challenge.
Therapeutic Efficacy of H5N1-HA–Specific Nanobodies
We next determined whether H5-VHHb Nanobody could be
used therapeutically. We administered 60 lg of this Nanobody
(3 mg/kg) intranasally to mice up to 72 h after challenge with
1 LD50 of NIBRG-14ma virus. At 4 days after challenge, animals
that had received H5-VHHb 4, 24 or 48 h after challenge had
significantly higher body weights and lower lung virus loads
than control mice (Figure 5). Although mice treated with H5-
VHHb Nanobody 72 h after challenge were not clinically pro-
tected compared with control mice, they had significantly lower
lung virus titers (Figure 5B). To exclude possible interference of
residual neutralizing Nanobodies in the TCID50 assay that was
used to determine the viral loads in lung virus extracts, the
amount of viral RNA in these extracts was also determined using
vRNA-specific quantitative reverse-transcription PCR. The re-
sults of this assay were completely in line with the determined
infectious virus load (Figure 5C). Because H5-VHHb Nanobody
showed the strongest prophylactic activity, its therapeutic effi-
cacy against a more lethal virus dose was determined. When
60 lg (3 mg/kg) of this VHHwas given 48 or 72 h after infection
with 4 LD50 of NIBRG-14ma, weight loss was lower than in
controls. In addition, treatment with nanobodies 48 h after in-
fection significantly delayed mortality compared with controls
(Figure 6).
Figure 3. Bivalent H5-VHHb is more protective than monovalent H5-VHHm. A, BALB/c mice received phosphate-buffered saline (PBS), H5-VHHm, or
H5-VHHb intranasally 24 h before challenge with the median lethal dose of NIBRG-14ma virus. Subsequently, body weight was measured daily and is
represented as the average percentage of body weight for all mice in each group. The difference in weight loss was significant between mice given 30,
60, 6, 0.25 or 0.5 lg of H5-VHHm/b and those given respiratory syncytial virus (RSV) VHHm/b (P, .01). Similarly, the difference was significant at P, .05
between mice receiving 12 or 1.2 lg of H5-VHHm/b and those receiving RSV-VHHm/b, and at P, .05 between all doses of H5-VHHm/b and PBS. B, All
mice were treated as described for A and killed on day 4 after infection, and lung virus titers were determined. Graphs represent mean virus titers
(median tissue culture infectious dose [TCID50]/mL lung homogenate) for all mice in each group; error bars, standard deviations of the mean; #, below
detection limit. *P , .05.
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Generation of H5-VHH Escape Variant H5N1 Virus
To identify the HA amino acid residues involved in H5-VHH
binding, we selected escape viruses by growth and plaque pu-
rification of NIBRG-14ma virus in the presence of H5-VHHm
or H5-VHHb Nanobodies. The HA sequences of 6 in-
dependently isolated H5-VHHm escape viruses revealed sub-
stitution of a lysine by a glutamic acid residue at position 189 in
HA1 (H5 numbering). In addition, 2 H5-VHHm escape
mutants carried an N154D substitution, and 4 carried an N154S
substitution. The 3-dimensional structure of NIBRG-14 HA
shows that N154D/S and K189E are close to each other as part
of the corresponding antigenic site B in H3 HA (Figure 7A)
[31, 33]. Interestingly, the N154D/S mutations remove an
N-glycosylation site, which presumably has evolved in H5N1
HA as a strategy to mask an antigenic site [34]. Escape viruses
selected in the presence of H5-VHHb carried only substitution
K189N (n 5 4) or K189E (n 5 2). Notably, 4 of the H5-VHHb
escape viruses had an additional D145N mutation located in
the stalk of HA2, 40 residues upstream of the membrane anchor
(Figure 7B). Based on hemagglutination inhibition and micro-
neutralization assays, the K189N/E substitution appears neces-
sary and sufficient to abolish binding to H5-VHHm or VHHb
Figure 4. H5-VHHb protects against morbidity and mortality after
H5N1 virus challenge. BALB/c mice (n 5 5 per group) were given
phosphate-buffered saline (PBS), 60 lg of respiratory syncytial virus (RSV)
VHHb, or 60 lg of H5-VHHb intranasally; 24 h later (day 0) they were
challenged with 4-fold the median lethal dose of NIBRG-14ma virus. Body
weight and survival were monitored daily for 14 days. A, Body weight
after infection is represented as the mean percentage of initial body
weight for all mice in each group. Error bars represent standard
deviations of the mean. There were significant differences in body weight
between mice treated with H5-VHHb and both PBS and RSV-VHHb groups
(P , .01) on day 5 after challenge. B, Kaplan-Meier survival curve of
experiment in A.
Figure 5. H5-VHHb inhibits H5N1 virus replication when adminis-
tered up to 72 h after challenge. BALB/c mice were challenged with
the median lethal dose of NIBRG-14ma virus. At 4, 24, 48, and 72 h
after challenge, mice were treated intranasally with phosphate-
buffered saline (PBS), 60 lg of control respiratory syncytial virus (RSV)
VHHb, or 60 lg of H5-VHHb. A, Body weight after infection is
represented as the mean percentage of initial body weight for all mice
in each group. Four days after infection, there were significant
differences in body weight (P , .05) between groups treated 4, 24, or
48 h after infection with H5-VHHb, RSV-VHHb, or PBS. B, Lung virus
titers on day 4 after infection are represented as average virus
titers (median tissue culture infectious dose [TCID50]/mL lung
homogenate) for all mice in each group. Statistically significant
differences between compared groups (indicated with brackets)
were obtained with *P , .05 or **P , .005. C, Viral genomic RNA
load in lung extracts sampled on day 4 after infection as determined
by quantitative reverse-transcription polymerase chain reaction
and expressed as arbitrary units (a.u.). Error bars represent standard
deviations of the mean.
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(Figure 7C and D). These results indicate that residues in
antigenic site B, at the top of HA and very close to the receptor
binding domain, are essential for neutralization by H5-VHHm/b.
DISCUSSION
Despite decades of research on antivirals to treat influenza, there
are still very few virus-directed options for the treatment of
patients with severe complications of influenza. Zoonotic
infections with H5N1 influenza viruses are rare, but the case-
fatality rate is 60% even when advanced supportive therapy is
applied [35]. We demonstrated that intranasal administration of
llama-derived immunoglobulin single-chain variable domain
fragments with in vitro neutralizing activity against H5N1
viruses can control virus replication and reduce morbidity and
mortality in a mouse model for H5N1 influenza. We also
showed that the in vivo neutralizing capacity of bivalent H5
HA–specific Nanobodies is superior to that of the monovalent
construct. Indeed, when mice were treated with as little as
25 lg/kg of H5-VHHb 24 h before challenge, virus titers in the
lungs were undetectable. Compared with treatment with an
irrelevant Nanobody, significant reductions in lung virus loads
were obtained by prophylactic administration of H5-VHHb up
to 2 days before challenge or by therapeutic treatment for up to
3 days after challenge.
Different groups of investigators have reported the isolation
and characterization of murine or human monoclonal anti-
bodies and single-chain variable fragment antibody fragments
that are reactive against H5 HA with specificity for a particular
clade of H5 HA [36], cross-clade reactivity [37–40], and even
reactive against multiple HA subtypes [41–44]. How do our
findings compare with these and findings of other studies that
have explored passive immunoprophylaxis as a promising
therapeutic against influenza? First, Nanobodies can be easily
produced in and purified from a prokaryotic or yeast expression
system. Second, Nanobodies can be engineered into multiple
configurations to produce, for example, bispecific, bivalent, or
pentavalent constructs [45]. Third, we chose the intranasal or
intrapulmonary route of administration because this allows
deposition and deep penetration of Nanobodies in the
respiratory tract. Fourth, H5-VHHb at 25 lg/kg was able to
control lung virus replication when administered 24 h before
challenge. In most other studies, passive immunotherapy was
applied at doses between 3 and 25 mg/kg. However, the
Figure 6. Therapeutic effect of H5-VHHb against severe H5N1 virus challenge. BALB/c mice (n5 5 per group) were challenged with 4-fold the median
lethal dose of NIBRG-14ma virus. At 48 or 72 h after challenge, mice were treated intranasally with phosphate-buffered saline (PBS), 60 lg of respiratory
syncytial virus (RSV) VHHb, or 60 lg of H5-VHHb. A, Body weight after infection is represented as the average percentage of body weight for all mice in
each group. Error bars represent standard deviations of the mean. Differences were significant on day 5 after challenge between mice treated with
H5-VHHb 48 h after infection and those treated with PBS or RSV-VHHb (P , .01). B, Kaplan-Meier survival curve for experiment in A. The difference in
survival rate is significant (P , .01) between control mice (treated with PBS or RSV-VHHb) and mice treated with H5-VHHb 48 h after infection.
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comparison of doses has to take into account the 10-fold lower
molecular mass of VHHmolecules compared with conventional
antibodies. Monovalent Nanobodies are small (15 kDa) and as
a result are removed rapidly from the blood through the kid-
neys. Their serum half-life is 30–60 min [46]. Half-life extension
methods used for other small antibody fragments, such as PE-
Gylation or fusion to serum albumin, could be used to tailor the
half-life of Nanobodies.
Conventional immunoglobulins are normally multivalent,
meaning that they have multiple paratopes for antigen binding.
Nevertheless, such immunoglobulins, including neutralizing
antibodies, mostly bind to a single virion with only one paratope
[47]. The distribution of the viral spikes and their accessibility
for antibody binding usually does not permit bivalent binding of
a conventional antibody to a single virion. In addition, the
flexibility of the 2 epitope-binding arms of an immunoglobulin
Figure 7. Isolation and characterization of in vitro VHH escape viruses. A, Schematic representation of the likely antigenic site recognized by H5-VHH
Nanobodies. NIBRG-14 hemagglutinin is represented as a ribbon in top and side views. Side chains of N154 and K189 (hemagglutinin 1 subunit and
H5 numbering) that are substituted in H5-VHHm/b escape viruses are shown in red. The receptor binding domain (RBD) is highlighted in one monomer
(top view). The image was generated using the PyMOL Molecular Graphics System (W. L. DeLano, 2002; DeLano Scientific) and Protein Data
Bank accession number 2IBX. B, Overview of amino acid substitutions in hemagglutinin of escape viruses obtained after growth of NIBRG-14ma virus on
Madin-Darby canine kidney cells in the presence of H5-VHHm (M) or H5-VHHb (B) Nanobodies. C, D, Wild-type NIBRG-14ma and escape virus
isolates (highlighted in bold in B) were used in hemagglutination inhibition (C) and microneutralization (D) assays; 4 hemagglutinin units of each virus
were used to agglutinate chicken erythrocytes in the presence of a 2-fold serial dilution of H5-VHHm (top) or H5-VHHb (bottom), and 100-fold the median
tissue culture infectious dose of NIBRG-14ma was used in the microneutralization assay. Eighteen hours after infection the amount influenza virus
nucleoprotein was determined by enzyme-linked immunosorbent assay of fixed cells.
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Gmolecule is limited, and therefore binding to a second epitope
on the surface of a single virion is possible only when that
epitope is very near. This paradigm of typically monovalent
interaction between a neutralizing monoclonal immunoglobulin
G and a viral spike protein has been elegantly addressed by
Wang and Yang [48]. Neutralization of human immunodefi-
ciency virus type 1 (HIV-1) by monoclonal antibody 2F5 was
100-fold enhanced when a second epitope for 2F5 was artificially
introduced at another position in the HIV-1 glycoprotein spike,
allowing bivalent interaction with increased binding avidity
between the antibody and the virion. It was also demonstrated
that such a bivalent binding occurs in trans, that is, by bridging
the natural and artificially introduced epitopes in 2 subunits
within a single HIV-1 trimer [48]. A similar mechanism may
explain the superior neutralization and protective efficacy of
bivalent H5-VHHb compared with H5-VHHm. The flexible
linker between the 2 paratope-containing domains in H5-VHHb
and its small size are compatible with a high-affinity bivalent
interaction with 2 epitopes within a single HA trimer.
A K189E substitution in HA1 was found to abolish the
neutralizing effect of H5-VHH. A Lys or Arg residue at this
position is conserved in all human H5N1 virus isolates. Of
note, all selected escape mutants contained a glutamic acid or
serine residue at position 189, which indicates that the con-
served positively charged amino acid is essential for H5-VHH
binding. Interestingly, escape mutants selected with H5-
VHHm also carried an N154D/S commutation that removes
an N-glycosylation site in this antigenic site of HA. The pre-
dicted N-glycosylation site at N154 in A/Hong Kong/156/97
HA was shown to be glycosylated [49]. This N-glycosylation in
H5 HA might have evolved to mask an antigenic site near the
receptor binding domain [50]. It may facilitate H5-VHHm
binding by increasing the thermodynamic stability of the epi-
tope, contributing to a productive interaction with monovalent
but not bivalent H5-VHH. Increased receptor affinity of
HA [32] in selected H5-VHH escape viruses in vitro is less
likely, because their susceptibility to receptor-destroying en-
zyme treatment is equal to that of the parental virus (results
not shown).
We conclude that neutralizing Nanobodies have consider-
able potential for the treatment of H5N1 virus infections. Al-
though we focused on VHHs that recognize an epitope near
the receptor binding domain, it is possible to select VHH
molecules that bind to other epitopes in HA, including more
conserved domains.
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